Drug Trial Radar · NCT01129024
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
Last checked: Nov 20, 2026Latest source record: Feb 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
19
Actual
Start
Apr 29, 2010
Primary completion
Jun 30, 2011
Study completion Jun 30, 2011
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
Conditions
- Immune Thrombocytopenia
Interventions
LusutrombopagDrug
tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: From first dose of study drug in the extension study up to 6 weeks after last dose; median (range) time on study treatment was 148 (10-387) days.
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Investigator
Anaheim, California
Investigator
Los Angeles, California
Investigator
Washington D.C., District of Columbia
Investigator
Boynton Beach, Florida
Investigator
Jacksonville, Florida
Investigator
Atlanta, Georgia
Investigator
Riverdale, Georgia
Investigator
Metairie, Louisiana
Investigator
Bethesda, Maryland
Investigator
Boston, Massachusetts
Investigator
Jefferson City, Missouri
Investigator
Kansas City, Missouri
Investigator
New Brunswick, New Jersey
Investigator
New York, New York
Investigator
New York, New York
Investigator
Cleveland, Ohio
Investigator
San Antonio, Texas
Investigator
Salt Lake City, Utah
Investigator
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.